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We tested 59 Greek patients with Behcet’s Disease (BD) for serum anti-Saccharo-
myces cerevisiae antibodies. No increase of  these antibodies was detected in the 
cases compared to 55 healthy unrelated blood donors from the same population. 
This finding is in contrast with the correlation between Saccharomyces cerevisiae 
antibodies and BD as reported in other populations. It seems that environmental 
factors may contribute to disease expression in different populations,  producing 
different effects according to the individual’s genetic predisposition.  Saccharomy-
ces cerevisiae antibodies do not seem to be of any significance in the Greek popu-
lation.
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Behcet’s Disease (BD), also called Adamantiades-BD, is an inflammatory disorder 
of unclear etiology that is ethnically related and more frequent among Middle 
Eastern and Asian populations.1,2
BD is common in populations dwelling along the path of the Old Silk Road, 
namely: Turks, Jews, Saudi, Iranians, Koreans, and Japanese; it is uncommon in 
Western populations.1,3 As the underlying condition is vasculitis, clinical manifes-
tations may vary from case to case to a large extent.4,5 The classical clinical picture 
includes uveitis, aphthous stomatitis, genital ulcers, and arthropathy. It may also 
include skin pathergy, gastrointestinal tract disease with abdominal pain and diar-
rhea, and many other manifestations that include the heart, vessels, and brain.6 Brain 
lesions may be life threatening and they are a major cause of disease mortality.7
The aetiology of BD remains unknown; some indications for a genetic factor 
exist, but no clear mode of inheritance has been established.8 The association with 
HLA antigens is notable.9,10 This association is common to different ethnic groups, 
but the effect size of the HLA type is smaller in the European populations stud-
ied.11 Interestingly, some have shown a relationship between  HLA phenotype and George Vaiopoulos, et al.
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turer’s protocol. The results are presented as arbitrary units.
Fig. 1. depicts the distribution of IgA and IgG values of 
ASCA titers in patients and controls. No significant differ-
ence of IgA or IgG titers was detected in A-BD patients 
compared to controls, using the  Student’s t-test statistical 
analysis as presented in Table 1.
The cause of BD remains unknown. The association with 
HLA types has been shown  in many populations including 
Greeks,17 but on an individual basis, this immuno-genetic 
association is of no strong diagnostic value. The role of en-
vironmental factors is not clear. Markers of diagnostic val-
ue may facilitate diagnosis especially in cases not fulfilling 
the diagnostic criteria as frequently occurs in the early stag-
es of the disease.15 
In this context, the presence of a laboratory marker asso-
ciated with the disease may be of practical value. BD shares 
some clinical similarities with Crohn’s Disease (CD) in terms 
of intestinal involvement (terminal ileum), arthritis, and uve-
itis. These similarities raise the possibility of common caus-
ative or pathogenetic factor(s) but, as is the case in BD, the 
etiology of CD remains obscure.15 Recently, an increased 
frequency of ASCA has been reported in CD patients, in-
cluding Greeks.18-20 The same antibodies were also detected 
in first degree relatives of patients with CD.21,22 This finding 
indicates either a common genetic element or similar expo-
prognosis.12 Since the disease has no specific characteristic 
findings, diagnosis is based solely on clinical criteria such 
as the combination of clinical manifestations proposed in 
1990 by the International Study Group for BD.13,14 Diagno-
sis may thus be delayed until all criteria are fulfilled. The 
detection of a specific laboratory marker would facilitate 
diagnosis.15    
In searching for factor(s) causing or  triggering the onset 
or exacerbation of the disease, several microorganisms 
have been incriminated, though clear indications for the di-
rect involvement of any infectious factor do not exist. Nev-
ertheless, it appears that saprophytes such as chlamydia tra-
chomatis can affect the course of the disease especially if a 
genetic predisposition exists.16 Therefore, early detection of 
an infectious agent or a marker for infection may be a use-
ful diagnostic test. In Greece, the association between anti-
Saccharomyces cerevisiae antibodies (ASCA) antibodies 
and BD, to the best of our knowledge, has not yet been 
studied.
We measured the serum ASCA titers in 58 Greek patients 
with a diagnosis of BD (30 males, 28 females) aged be-
tween 17 and 70 years (mean age 38.5 y). All 58 BD cases 
fulfilled the standard International Study Group criteria for 
BD.13 Four cases out of the 58 complained of abdominal 
symptoms including recurrent diarrhea, pain, nausea, and 
constipation; no patient had been subjected to an endosco-
py. All cases were regularly followed in the Rheumatology 
Clinic of our Department. Informed consent was given by 
all patients studied. Fifty five healthy unrelated blood do-
nors from the same population matched for sex and age 
were used as controls. The ASCA serum titers were mea-
sured with a commercially available ELISA kit (ASCA 
IgG, ASCA IgA, QUANTA Lite, INOVA Diagnostics, San 
Diego, CA, USA). Both serum IgG and IgA levels of 
ASCA were separately titrated according to the manufac-
Table 1. Statistical Analysis of the Titers of IgA and IgG Serum 
ASCA Levels in 58 BD Greek Patients and in 56 Healthy Blood 
Donors from the Same Population
Patients Controls
No 58 56
IgA 5.785 ± 6.66 12.4 ± 8.72
t-test -1.54
IgG 7.495 ± 0.97 7.21 ± 6.06
t-test 0.251
ASCA, anti-Saccharomyces cerevisiae antiodies; BD, Behcet’s disease.
Fig. 1. Distribution of IgA and IgG serum ASCA levels in 58 Greek BD patients and 55 healthy blood donors from the same population. ASCA, anti-Saccharo-
myces cerevisiae antiodies.
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patients did not achieve any diagnostic value. ASCA testing 
may contribute to better diagnosis of BD in some ethnic 
groups but, on this topic, more data on European popula-
tions are needed. 
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